- Motif Bio said new data regarding its antibiotic development work had been presented at a key conference in San Francisco.

The iclaprim data were presented at the American Society For Microbiology Microbe 2019, running from June 20-24.

'The posters presented at ASM Microbe include additional data from the Phase 3 clinical trials with iclaprim in bacterial skin and skin structure infections,' chief medical officer David Huang said

The additional date showed improvements in efficacy parameters and Cmax with a fixed dosing regimen compared to a weight-based dose regimen, among other findings.

At 9:45am: [LON:MTFB] Motif Bio Plc Ord 1p share price was -0.29p at 2.44p

Story provided by